Lycia Therapeutics, Inc. (LYCA) stock analysis
LYCANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$31.35+0.43 (+1.39%)
Close on Nov 18, 2026Market cap –P/E –Yield –
Analysis
Not enough annual history yet
Analysis needs at least two fiscal years of reported financials for Lycia Therapeutics.
See a number that looks wrong?